Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer

NCT02151721 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

DRUG: Vorinostat, gefitinib

Sponsor

Kanazawa University